<DOC>
	<DOC>NCT01394666</DOC>
	<brief_summary>The purpose of this study is to evaluate treatment patterns and associated outcomes for CP-CML patients who fail Imatinib 400 mg daily in a real-world setting.</brief_summary>
	<brief_title>Non-interventional Treatment Patterns Study in Chronic Phase Chronic Myelogenous Leukemia (CP-CML)</brief_title>
	<detailed_description>Time Perspective: Retrospective and Prospective</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia, Myeloid, Chronic-Phase</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com. Adult patients (18 years or older) in Chronic phase CML patients who have been treated with Imatinib 400 mg and have failed.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>